Matching-Adjusted Indirect Comparison Study: Health-related Quality of Life in RRMM Patients Treated with Ide-Cel vs Belantamab Mafodotin Presented at EHA 2022
Dr.Nina Shah Discusses Health-related Quality of Life in RRMM Patients Treated with Idecabtagene Vicleucel (Ide-Cel) vs Belantamab Mafodotin in Matching-Adjusted Indirect Comparison Study
Abstract Title:
Health-related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Idecabtagene Vicleucel vs Belantamab Mafodotin: A Matching-Adjusted Indirect Comparison Study
What is the purpose of this trial?
To compare health-related quality of life outcomes for triple-class exposed (TCE) relapsed/refractory multiple myeloma patients treated with ide-cel vs belantamab mafodotin.
RRMM patients who are triple-class exposed (TCE) to an immunomodulatory imide drug (IMiD® agent), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb) have poor clinical outcomes and poor health-related quality of life (HRQoL). The B-cell maturation antigen (BCMA)-directed CAR T cell therapy idecabtagene vicleucel (ide-cel, bb2121) received regulatory approval in the US for patients with RRMM with ≥4 prior lines of therapy (LOT), including an IMiD agent, PI, and anti-CD38 mAb, and in Europe and Japan for patients with RRMM with ≥3 prior LOTs including an IMiD agent, PI, and anti-CD38 mAb.
Ide-cel showed frequent, deep, and durable responses in TCE pts with RRMM in KarMMa, a phase 2, single-arm trial. Clinically meaningful improvements in HRQoL outcomes vs baseline were observed.
The BCMA-targeted antibody-drug conjugate belantamab mafodotin was approved in the US and Europe for patients with RRMM with ≥4 prior LOTs including an IMiD agent, PI and anti-CD38 mAb, based on data from the phase 2, single-arm DREAMM-2 trial. There is a paucity of evidence comparing HRQoL for different treatment options approved in RRMM.
In this video:
Dr.Nina Shah (UCSF Helen Diller Family Comprehensive Cancer Center—San Francisco, CA) discusses health-related quality of life (HRQoL) in relapsed/refractory mulitple myeloma (RRMM) patients treated with ide-cel vs belantamab mafodotin in matching-adjusted indirect comparison study.
Conclusion:
While this analysis was limited by the availability of aggregate data from DREAMM-2, which may influence the outcomes of interest, results suggest that one-time treatment with ide-cel offers improved HRQoL vs belantamab mafodotin across the EORTC quality of life questionnaire (QLQ-C30) pain, fatigue, and global health status/QoL domains, as well as the QLQ-MY20 pain domain.
Clinical trial information: NCT03361748, NCT03525678
